利奈唑胺对EICU内耐甲氧西林金黄色葡萄球菌肺部感染的临床疗效观察

Clinical efficacy of linezolid for pulmonary infections caused by MRSA in EICU

目的观察利奈唑胺治疗EICU内耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染的临床疗效。方法 56例MRSA肺部感染患者随机分为观察组和对照组各28例,两组均给予常规治疗外,对照组给予万古霉素、观察组给予利奈唑胺治疗;14d后比较两组疗效。结果利奈唑胺组总有效率为82.1%,明显优于万古霉素组的53.6%,差异有统计学意义(P<0.05);利奈唑胺组的细菌清除率为78.6%,明显优于万古霉素组的46.4%,差异有统计学意义(P<0.05);两组患者治疗后外周血白细胞均明显下降,但两组相比,差异无统计学意义。结论利奈唑胺治疗EICU内MRSA肺部感染的疗效显著,安全性好,值得在临床推广。

OBJECTIVE To observe the clinical efficacy of linezolid for MRSA pulmonary infections in EICU.METHODS A total of 56 patients with MRSA pulmonary infections were randomly divided into the test group and the control group,28 cases in each group.The two groups were given conventional treatment.The control group was given vancomycin,while the test group was given linezolid,then the clinical efficacy of the two groups was compared 14 days after the treatment.RESULTS The total effective rate of test group was 82.1%,significantly higher than 536.6% of the control group,the difference was statistically significant（P〈0.05）;the rate of bacterial clearance of the test group was 78.6%,significantly higher than 46.4% of the control group,the difference was statistically significant（P〈0.05）.The peripheral blood leukocytes of the both groups were significantly decreased after the treatment,but the difference was not statistically significant.CONCLUSION Linezolid is with significant efficacy and safety in treatment of MRSA pulmonary infections in EICU,which is worthy of the clinical promotion.